Market closed

Eli Lilly/$LLY

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Eli Lilly

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Ticker

$LLY

Sector

Health Care

Trading on

NYSE

Industry

Pharmaceuticals

Headquarters

Indianapolis, United States

Employees

43,000

Website

www.lilly.com

Eli Lilly Metrics

BasicAdvanced

$718B

86.22 $9.25

0.43 $5.20

0.75%

Price and volume

Market cap

$718B

Beta

0.43

52-week high

$972.53

52-week low

$612.70

Average daily volume

3.1M

Dividend rate

$5.20

Financial strength

Current ratio

1.273

Quick ratio

0.63

Long term debt to equity

203.322

Total debt to equity

218.081

Dividend payout ratio (TTM)

54.12%

Interest coverage (TTM)

18.52%

Management effectiveness

Return on assets (TTM)

13.95%

Return on equity (TTM)

65.32%

Valuation

Price to earnings (TTM)

86.222

Price to revenue (TTM)

17.578

Price to book

50.39

Price to tangible book (TTM)

370.99

Price to free cash flow (TTM)

-411.772

Dividend yield (TTM)

0.65%

Forward dividend yield

0.75%

Growth

Revenue change (TTM)

27.41%

Earnings per share change (TTM)

67.52%

3-year revenue growth (CAGR)

13.76%

3-year earnings per share growth (CAGR)

12.19%

3-year dividend per share growth (CAGR)

15.20%

What the Analysts think about Eli Lilly

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Eli Lilly stock.

Eli Lilly Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Eli Lilly Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Eli Lilly News

AllArticlesVideos

Watch These Eli Lilly Price Levels as Stock Slumps on Tepid Sales Outlook

Investopedia·2 hours ago

Eli Lilly and Company (LLY) CEO Dave Ricks presents at 43rd Annual J.P. Morgan Healthcare Conference (Transcript)

Seeking Alpha·5 hours ago

Buy the weakness in Eli Lilly, says Mizuho Healthcare Strategist Jared Holz

CNBC Television·7 hours ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $LLY

$

Capital at risk

Market closed

Upcoming events

Feb14

Eli Lilly

Dividend·Ex-dividend

Mar10

Eli Lilly

Dividend·Payment

$1.50

Per share

FAQs

What’s the current market cap for Eli Lilly stock?

Eli Lilly (LLY) has a market cap of $718B as of January 15, 2025.

What is the P/E ratio for Eli Lilly stock?

The price to earnings (P/E) ratio for Eli Lilly (LLY) stock is 86.22 as of January 15, 2025.

Does Eli Lilly stock pay dividends?

Yes, the Eli Lilly (LLY) stock pays dividends to shareholders. As of January 15, 2025, the dividend rate is $5.2 and the yield is 0.75%. Eli Lilly has a payout ratio of 54.12% on a trailing twelve-month basis.

When is the next Eli Lilly dividend payment date?

The next Eli Lilly (LLY) dividend payment is scheduled for March 10, 2025.

What is the beta indicator for Eli Lilly?

Eli Lilly (LLY) has a beta rating of 0.43. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.